Drug-induced interstitial lung disease caused by olaparib: three case reports and review of the Japanese Adverse Drug Event Report database and literature
Abstract Background Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has demonstrated effectiveness in treating ovarian, breast, and other cancers, particularly those with specific molecular subtypes including, but not limited to, BRCA1/2 mutations. Consequently, its utilization is expecte...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-08-01
|
| Series: | BMC Pulmonary Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12890-023-02569-3 |
| _version_ | 1827724940907905024 |
|---|---|
| author | Hiroshi Ishimoto Noriho Sakamoto Takashi Kido Mutsumi Ozasa Shin Tsutsui Mayako Mori Daichi Setoguchi Shinnosuke Takemoto Yasushi Obase Yuji Ishimatsu Chiharu Tomonaga Kanako Matsumoto Sachiko Morisaki Kiyonori Miura Hiroshi Mukae |
| author_facet | Hiroshi Ishimoto Noriho Sakamoto Takashi Kido Mutsumi Ozasa Shin Tsutsui Mayako Mori Daichi Setoguchi Shinnosuke Takemoto Yasushi Obase Yuji Ishimatsu Chiharu Tomonaga Kanako Matsumoto Sachiko Morisaki Kiyonori Miura Hiroshi Mukae |
| author_sort | Hiroshi Ishimoto |
| collection | DOAJ |
| description | Abstract Background Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has demonstrated effectiveness in treating ovarian, breast, and other cancers, particularly those with specific molecular subtypes including, but not limited to, BRCA1/2 mutations. Consequently, its utilization is expected to increase in the future. For this reason, it is important to acknowledge the potential for adverse events associated with olaparib, including the relatively rare but significant risk of drug-induced interstitial lung disease (DIILD). Since DIILD can lead to fatal outcomes, its early detection is crucial. The dissemination of knowledge regarding DIILD can be facilitated through case reports; however, specific reports of DIILD caused by olaparib have only been published in Japanese. To the best of our knowledge, this is the first report in English of our experience with three cases of DIILD caused by olaparib. Case presentation Cases 1, 2, and 3 involved Japanese women with ovarian cancer who had been receiving olaparib at a dose of 600 mg/day. Case 1, a 72-year-old woman who had been on olaparib for 4 months, and case 2, a 51-year-old woman who had been on olaparib for 8 months, reported fever and general malaise. Chest computed tomography (CT) revealed pale ground glass opacity (GGO) similar to hypersensitivity pneumonitis. The severity grade was 2 in both cases. Case 3, a 78-year-old woman who had been on olaparib for 3 weeks, presented with cough and reported dyspnea on exertion. Chest CT revealed non-specific interstitial pneumonia and organizing pneumonia-like shadows. The severity grade was 4. Olaparib was discontinued in all cases. Case 1 received 0.6 mg/kg of prednisolone due to mild hypoxia, while prednisolone was not administered in case 2 due to the absence of hypoxia. Case 3 received steroid pulse therapy due to severe hypoxia. Olaparib administration was not resumed in any patient. Conclusion DIILD caused by olaparib in Japan, including the present three cases, commonly presents with GGO, similar to hypersensitivity pneumonitis on chest CT. The prognosis for the majority of patients is favorable; however, there have been instances of severe cases. Early recognition of drug-induced lung injury and further accumulation of cases is important. |
| first_indexed | 2024-03-10T22:22:32Z |
| format | Article |
| id | doaj.art-bbc66205674c44a1a3037f3efb4be317 |
| institution | Directory Open Access Journal |
| issn | 1471-2466 |
| language | English |
| last_indexed | 2024-03-10T22:22:32Z |
| publishDate | 2023-08-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Pulmonary Medicine |
| spelling | doaj.art-bbc66205674c44a1a3037f3efb4be3172023-11-19T12:15:09ZengBMCBMC Pulmonary Medicine1471-24662023-08-012311910.1186/s12890-023-02569-3Drug-induced interstitial lung disease caused by olaparib: three case reports and review of the Japanese Adverse Drug Event Report database and literatureHiroshi Ishimoto0Noriho Sakamoto1Takashi Kido2Mutsumi Ozasa3Shin Tsutsui4Mayako Mori5Daichi Setoguchi6Shinnosuke Takemoto7Yasushi Obase8Yuji Ishimatsu9Chiharu Tomonaga10Kanako Matsumoto11Sachiko Morisaki12Kiyonori Miura13Hiroshi Mukae14Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical SciencesDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical SciencesDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical SciencesDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical SciencesDepartment of Radiology, Nagasaki University Graduate School of Biomedical SciencesDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical SciencesDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical SciencesDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical SciencesDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical SciencesDepartment of Nursing, Nagasaki University Graduate School of Biomedical SciencesDepartment of Obstetrics and Gynecology, Nagasaki University Graduate School of Biomedical SciencesDepartment of Obstetrics and Gynecology, Nagasaki University Graduate School of Biomedical SciencesDepartment of Obstetrics and Gynecology, Nagasaki University Graduate School of Biomedical SciencesDepartment of Obstetrics and Gynecology, Nagasaki University Graduate School of Biomedical SciencesDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical SciencesAbstract Background Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has demonstrated effectiveness in treating ovarian, breast, and other cancers, particularly those with specific molecular subtypes including, but not limited to, BRCA1/2 mutations. Consequently, its utilization is expected to increase in the future. For this reason, it is important to acknowledge the potential for adverse events associated with olaparib, including the relatively rare but significant risk of drug-induced interstitial lung disease (DIILD). Since DIILD can lead to fatal outcomes, its early detection is crucial. The dissemination of knowledge regarding DIILD can be facilitated through case reports; however, specific reports of DIILD caused by olaparib have only been published in Japanese. To the best of our knowledge, this is the first report in English of our experience with three cases of DIILD caused by olaparib. Case presentation Cases 1, 2, and 3 involved Japanese women with ovarian cancer who had been receiving olaparib at a dose of 600 mg/day. Case 1, a 72-year-old woman who had been on olaparib for 4 months, and case 2, a 51-year-old woman who had been on olaparib for 8 months, reported fever and general malaise. Chest computed tomography (CT) revealed pale ground glass opacity (GGO) similar to hypersensitivity pneumonitis. The severity grade was 2 in both cases. Case 3, a 78-year-old woman who had been on olaparib for 3 weeks, presented with cough and reported dyspnea on exertion. Chest CT revealed non-specific interstitial pneumonia and organizing pneumonia-like shadows. The severity grade was 4. Olaparib was discontinued in all cases. Case 1 received 0.6 mg/kg of prednisolone due to mild hypoxia, while prednisolone was not administered in case 2 due to the absence of hypoxia. Case 3 received steroid pulse therapy due to severe hypoxia. Olaparib administration was not resumed in any patient. Conclusion DIILD caused by olaparib in Japan, including the present three cases, commonly presents with GGO, similar to hypersensitivity pneumonitis on chest CT. The prognosis for the majority of patients is favorable; however, there have been instances of severe cases. Early recognition of drug-induced lung injury and further accumulation of cases is important.https://doi.org/10.1186/s12890-023-02569-3OlaparibDrug-induced interstitial lung diseaseHypersensitivity pneumonitis like patternOvarian cancerPARP inhibitorCase report |
| spellingShingle | Hiroshi Ishimoto Noriho Sakamoto Takashi Kido Mutsumi Ozasa Shin Tsutsui Mayako Mori Daichi Setoguchi Shinnosuke Takemoto Yasushi Obase Yuji Ishimatsu Chiharu Tomonaga Kanako Matsumoto Sachiko Morisaki Kiyonori Miura Hiroshi Mukae Drug-induced interstitial lung disease caused by olaparib: three case reports and review of the Japanese Adverse Drug Event Report database and literature BMC Pulmonary Medicine Olaparib Drug-induced interstitial lung disease Hypersensitivity pneumonitis like pattern Ovarian cancer PARP inhibitor Case report |
| title | Drug-induced interstitial lung disease caused by olaparib: three case reports and review of the Japanese Adverse Drug Event Report database and literature |
| title_full | Drug-induced interstitial lung disease caused by olaparib: three case reports and review of the Japanese Adverse Drug Event Report database and literature |
| title_fullStr | Drug-induced interstitial lung disease caused by olaparib: three case reports and review of the Japanese Adverse Drug Event Report database and literature |
| title_full_unstemmed | Drug-induced interstitial lung disease caused by olaparib: three case reports and review of the Japanese Adverse Drug Event Report database and literature |
| title_short | Drug-induced interstitial lung disease caused by olaparib: three case reports and review of the Japanese Adverse Drug Event Report database and literature |
| title_sort | drug induced interstitial lung disease caused by olaparib three case reports and review of the japanese adverse drug event report database and literature |
| topic | Olaparib Drug-induced interstitial lung disease Hypersensitivity pneumonitis like pattern Ovarian cancer PARP inhibitor Case report |
| url | https://doi.org/10.1186/s12890-023-02569-3 |
| work_keys_str_mv | AT hiroshiishimoto druginducedinterstitiallungdiseasecausedbyolaparibthreecasereportsandreviewofthejapaneseadversedrugeventreportdatabaseandliterature AT norihosakamoto druginducedinterstitiallungdiseasecausedbyolaparibthreecasereportsandreviewofthejapaneseadversedrugeventreportdatabaseandliterature AT takashikido druginducedinterstitiallungdiseasecausedbyolaparibthreecasereportsandreviewofthejapaneseadversedrugeventreportdatabaseandliterature AT mutsumiozasa druginducedinterstitiallungdiseasecausedbyolaparibthreecasereportsandreviewofthejapaneseadversedrugeventreportdatabaseandliterature AT shintsutsui druginducedinterstitiallungdiseasecausedbyolaparibthreecasereportsandreviewofthejapaneseadversedrugeventreportdatabaseandliterature AT mayakomori druginducedinterstitiallungdiseasecausedbyolaparibthreecasereportsandreviewofthejapaneseadversedrugeventreportdatabaseandliterature AT daichisetoguchi druginducedinterstitiallungdiseasecausedbyolaparibthreecasereportsandreviewofthejapaneseadversedrugeventreportdatabaseandliterature AT shinnosuketakemoto druginducedinterstitiallungdiseasecausedbyolaparibthreecasereportsandreviewofthejapaneseadversedrugeventreportdatabaseandliterature AT yasushiobase druginducedinterstitiallungdiseasecausedbyolaparibthreecasereportsandreviewofthejapaneseadversedrugeventreportdatabaseandliterature AT yujiishimatsu druginducedinterstitiallungdiseasecausedbyolaparibthreecasereportsandreviewofthejapaneseadversedrugeventreportdatabaseandliterature AT chiharutomonaga druginducedinterstitiallungdiseasecausedbyolaparibthreecasereportsandreviewofthejapaneseadversedrugeventreportdatabaseandliterature AT kanakomatsumoto druginducedinterstitiallungdiseasecausedbyolaparibthreecasereportsandreviewofthejapaneseadversedrugeventreportdatabaseandliterature AT sachikomorisaki druginducedinterstitiallungdiseasecausedbyolaparibthreecasereportsandreviewofthejapaneseadversedrugeventreportdatabaseandliterature AT kiyonorimiura druginducedinterstitiallungdiseasecausedbyolaparibthreecasereportsandreviewofthejapaneseadversedrugeventreportdatabaseandliterature AT hiroshimukae druginducedinterstitiallungdiseasecausedbyolaparibthreecasereportsandreviewofthejapaneseadversedrugeventreportdatabaseandliterature |